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Methamphetamine’s (METH) neurotoxicity is thought to be in part due to its ability to induce bloodebrain
barrier (BBB) dysfunction. Here, we investigated the effect of METH on barrier properties of cultured rat
primary brain microvascular endothelial cells (BMVECs). Transendothelial ﬂux doubled in response to
METH, irrespective of the size of tracer used. At the same time, transendothelial electrical resistance was
unchanged as was the ultrastructural appearance of inter-endothelial junctions and the distribution of key
junction proteins, suggesting that METH promoted vesicular but not junctional transport. Indeed, METH
signiﬁcantly increased uptake of horseradish peroxidase into vesicular structures. METH also enhanced
transendothelial migration of lymphocytes indicating that the endothelial barrier against both molecules
and cells was compromised. Barrier breakdown was only observed in response to METH at low micro-
molar concentrations, with enhanced vesicular uptake peaking at 1 mM METH. The BMVEC response to
METH also involved rapid activation of endothelial nitric oxide synthase and its inhibition abrogated
METH-induced permeability and lymphocyte migration, indicating that nitric oxide was a keymediator of
BBB disruption in response to METH. This study underlines the key role of nitric oxide in BBB function and
describes a novel mechanism of drug-induced ﬂuid-phase transcytosis at the BBB.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The BBB regulates the exchange of nutrients, waste and immune
cells between the blood and the nervous tissue of the central
nervous system (CNS) and is the most important component
preserving CNS homeostasis and neuronal function (Abbott et al.,
2010). Barrier function is epitomised by the restriction of ionic
currents across the BBB, with electrical resistance reaching 1500e
2000 U cm2 in vivo (Crone and Olesen, 1982; Butt et al., 1990).
The barrier-conferring cellular equivalent of the BBB are the
endothelial cells (ECs) of the brain capillary network. However
associated pericytes, astrocytes and the basement membrane also
play an additional regulatory and structural role. Many BBB
mechanisms can be modelled in vitro using monocultures of brain
microvascular endothelial cells (BMVECs) (Perriere et al., 2007;
Roux and Couraud, 2005). Importantly, such BMVEC models retainx: þ44 207 608 6810.
).
-NC-ND license.the features that render the BBB such a formidable barrier, namely
a full complement of tight junctions (TJs), lack of fenestrations and
low ﬂuid-phase endocytosis (pinocytosis) (Abbott et al., 2010). At
the healthy BBB, molecule transport in and out of the CNS is carried
out by carrier-mediated transport systems or receptor- and
adsorptive-mediated transcytosis. In certain- mostly pathological-
conditions, molecules can also cross the BBB endothelium non-
speciﬁcally via a paracellular pathway. Indeed, BBB dysfunction
involving transient or even chronic opening of TJs contributes to the
pathogenesis of many diverse CNS pathologies, such as epilepsy,
Parkinson’s and Alzheimer’s disease, andmultiple sclerosis (Forster,
2008; Zlokovic, 2008). More anecdotally, enhanced ﬂuid-phase
endocytosis or (macro)pinocytosis has been reported in BBB ECs
in response to hypoxic or ischemic conditions (Kaur and Ling,
2008), indicating that this is a transport feature which is rarely
used by either the healthy or diseased BBB.
Methamphetamine (METH) is a highly addictive psychostimu-
lant with neurotoxic features. Like other amphetamines and
presumably because of its similarity to dopamine, METH causes
monoamine release at neuronal synapses, primarily through the
T. Martins et al. / Neuropharmacology 65 (2013) 74e82 75inhibition of plasmalemmal transporters such as the dopamine
transporter or the serotonin transporter (Cruickshank and Dyer,
2009). It also causes long-term damage to monoaminergic nerve
terminals, as well as excitotoxicity, mitochondrial dysfunction and
increased production of reactive oxygen and nitrogen species (ROS
and RNS, respectively) (Quinton and Yamamoto, 2006). Because of
its small size and lipophilicity, METH readily crosses the BBB by
non-speciﬁc diffusion. In addition, METH can induce BBB
dysfunction in rodents (Kiyatkin et al., 2007; Sharma and Ali, 2006),
in particular in the limbic region (Bowyer and Ali, 2006) including
the hippocampus (Martins et al., 2011). It is now assumed that, in
addition to direct damage of monoaminergic nerve terminals, the
deregulation of the BBB in these brain areas potentially contributes
to widespread METH-induced neurotoxicity.
Nitric oxide synthases (NOS) convert L-arginine to produce the
secondmessenger nitric oxide (NO). TwoNOS isoforms exist in ECs:
endothelial NOS (eNOS), which is expressed constitutively, and
inducible NOS (iNOS), which is synthesised and utilized during
long-term adaptation of the vasculature (Michel and Feron, 1997).
In vascular ECs, eNOS regulates many key functions including
angiogenesis, inﬂammatory and anti-inﬂammatory processes, and
is the main NOS system regulating barrier function and perme-
ability (Fukumura et al., 2001; Schubert et al., 2002). The activity of
eNOS is primarily regulated by reversible phosphorylation in
response to various stimuli including vascular endothelial growth
factor (VEGF), insulin or shear stress, and phosphorylation on S1177
is considered to be a reliable indicator of its activation status
(Fleming, 2010). The activation and activity of eNOS is also inti-
mately linked to that of caveolin-1 and caveolae and thus ﬂuid-
phase endocytosis (Simionescu et al., 2009).
The purpose of the present study was to investigate the effect
of METH in a system of primary BMVECs with very well-preserved
TJs and barrier function. BMVEC permeability and the underlying
mechanism were evaluated in response to METH exposure. Since
pathophysiological BBB breakdown is often associated with
enhanced leukocyte inﬁltration, alterations to lymphocyte migra-
tion were also studied. METH effects were assessed at concentra-
tions, which are physiologically signiﬁcant, i.e. at levels found in
drug abusers. Finally, since NO production may play an important
role in METH-induced monoaminergic neurotoxicity (Imam et al.,
2000), we tested the role of eNOS in the METH-induced EC
response.
2. Materials and methods
2.1. Materials
Unless otherwise stated all materials were from Sigma. METH was provided by
Drs Nuno Milhazes (Institute of Health Sciences-North, Gandra PRD, Portugal) and
Fernanda Borges (Faculty of Sciences, University of Oporto, Portugal).
2.2. Brain microvascular endothelial cells (BMVECs)
Microvessels were isolated from brains of 6e8 week-old female Lewis rats
(Abbott et al., 1992) and seeded onto collagen IV/ﬁbronectin-coated tissue culture
ware or 12-mm Costar Transwells (3460) at high density (vessels from 6 rat brains
per 40 cm2). Cells were grown in EGM2-MV (Lonza, Wokingham, United Kingdom)
[with 5 mg/ml puromycin during the ﬁrst 5 days (Perriere et al., 2007)] for 2e3weeks
until their transendothelial electric resistance (TEER) plateaued at values above
200 U cm2. The immortalized Lewis rat cell line GPNT, which maintains many of
the signalling and metabolic features of primary BMVECs (but not TJs and well-
developed barrier properties) (Martinelli et al., 2009; Roux and Couraud, 2005)
wasmaintained inHam’s F10 supplementedwith 10% foetal calf serum, 2 ng/ml bFGF,
80 mg/ml heparin, 100 U/ml penicillin and 100 mg/ml streptomycin.
2.3. Transendothelial ﬂux
Fluorescein (FITC) or rhodamine B isothiocyanate (RITC)-dextran of 4, 70 or
250 kDa was added at 1 mg/ml to the apical side of BMVEC grown on 12-mm
Transwell ﬁlters. Samples (50 ml) were removed from the basal chamber (andreplaced by fresh medium) at 20e30 min intervals for 120 min before and after
addition of METH and/or L-NG-Nitroargininemethyl ester (L-NAME). Fluorescence of
samples was measured in a FLUOstar OPTIMA microplate reader (BMG LABTECH,
Aylesbury, UK), plotted against time and permeability changes were determined
from linear slope changes before and after addition of compounds.
2.4. Transendothelial electrical resistance (TEER)
TEER of primary brain EC monolayers was measured using STX-2 chopstick
electrodes connected to an EVOM epithelial voltohmmeter (World Precision
Instruments, Herts, UK). Real time TEER changes during METH treatment were
monitored by impedance spectroscopy using a 1600R ECIS system (Applied
Biophysics, Troy, NY, USA). For this, ECs were seeded on collagen type IV/ﬁbronectin-
coated 8W10E electrode arrays (Applied Biophysics). Impedance was measured at
4000 Hz at 10-min intervals. After the cells reached stable impedance, the ECs were
either left untreated or treated with 1 or 50 mMMETH. Results were normalised and
averaged from at least 3 independent experiments.
2.5. Immunocytochemistry
Conﬂuent BMVECs were ﬁxed in 80% methanol, 3.2% formaldehyde, 0.05 M
HEPES, pH 7.4 (20 C) for 5 min and then processed for indirect immunocyto-
chemistry (Turowski et al., 2004). Primary antibodies included afﬁnity puriﬁed anti-
vascular endothelial cadherin (VEC) (see supplemental Material and Methods for
more details), and anti-claudin-5 (1:100), occludin (1:50) and zonula occludens
(ZO)-1 (1:50) (Zymed Lab, San Francisco, CA, USA). Immunostained preparations
were mounted using Moviol 4-88 and analysed on a confocal laser-scanning
microscopy LSM 700 system (Carl Zeiss, Hertfordshire, UK). Series of overlapping
0.35 mm sections spanning the entire cell thickness were recorded.
2.6. Horseradish peroxidase uptake and transport
For transport studies, horseradish peroxidase (HRP, 10 mg/ml) was added with
or without 1 mMMETH to the apical side of conﬂuent primary BMVECs grown on 12-
mm Costar Transwells ﬁlters. After 1 h cells were washed 3 times with warm HBSS
containing Ca2þ and Mg2þ and new medium was added. Samples (100 ml) were
removed from the basal chamber (and replaced by fresh medium) at 30-min
intervals for 120 min. Samples were reacted with 100 ml of 1 mg/ml o-phenyl-
enediamine and 1 ml/ml of 30% hydrogen peroxide and, after colour appearance,
stopped with 100 ml of 1 N HCl. Absorbance of each sample was measured in
a FLUOstar OPTIMA microplate reader (BMG LABTECH, Aylesbury, UK). HRP activity
was plotted against time and rates determined by linear regression.
Uptake studies were performed in a similar fashion. Primary BMVECs grown in
96-well plates were treated with METH at various concentrations and for up to
70 min as speciﬁed in the Figure Legends. Subsequently, HRP (1 mg/ml) was added
for 5e30min (optimal times were determined as shown in Suppl. Fig. S3). Cells were
then extensively washed with warm HBSS and lysed with 50 ml of 1% Triton X-100 in
PBS before adding o-phenylenediamine and hydrogen peroxide.
2.7. Electron microscopy
Primary ECs were grown to conﬂuence on collagen type IV/ﬁbronectin-coated
polycarbonate ﬁlters. Cells were either directly processed for ﬁxation or, for the
visualisation of vesicular uptake, HRP (10 mg/ml) was added to the apical side of
cells, and cells either left untreated or treated with METH (1 mM). Where indicated,
ECs were preincubated with L-NAME (1 mM, 1 h) before HRP and METH addition.
After 1 h of incubation, monolayers were washed with DPBS and then ﬁxed in 2%
paraformaldehyde, 2% glutaraldehyde, in 0.05 M cacodylate buffer for 30 min. For
the diaminobenzide (DAB) reaction, cells were incubated with 3% DAB, 30%
hydrogen peroxide and imidazole in the dark for 30 min at RT. Cells were then
incubated with 1.5% potassium ferricyanide, 1% Osmium tetroxide for 1 h in the dark
at 4 C, followed by a dehydration step, and ﬁnally embedded in Epon resin. The
specimens were sectioned at 70 nm with no post-staining and visualised on a JEOL
1010 transmission electron microscope. The area and number of HRP-containing
structures from METH treated-cells were normalised to the control values from
non-treated cells, and represented as average per 1000 mm2 of cytoplasm.
2.8. Western blotting
Primary or GPNT ECs were grown on collagen I-coated 35-mm dishes, and, at
conﬂuence, cultured in serum-free medium overnight. Cells were treated as detailed
in the ﬁgure legends and then processed for western blot analysis as described
previously (Martinelli et al., 2009).
2.9. Transendothelial lymphocyte migration
Primary or GPNT BMVECs were grown to conﬂuence in collagen I-coated 96-
well plates, and treated as indicated in ﬁgure legends. Cells were washed exten-
sively and then, 2  105/myelin basic protein (MBP)-speciﬁc rat lymphocytes were
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adhesion rates were determined by time-lapse video microscopy as described
(Adamson et al., 1999). Migration data was collected from multiple experiments,
each representing a minimum of six wells.
2.10. Statistical analyses
Statistics were performed using one-way ANOVA, followed by Dunnett’s or
Bonferroni’s post-test, or Student’s t-test, as indicated in the Figure Legends. Data
are presented as mean  SEM, and the level of P < 0.05 was accepted as statistically
signiﬁcant.
3. Results
3.1. METH induces macromolecular ﬂux across brain microvascular
EC monolayers without affecting TEER
To investigate cellular and molecular mechanisms underlying
METH-induced changes of the BBB we studied the response of
BMVECs toMETH in vitro. Unless stated otherwise, freshly prepared
primary rat BMVEC (Perriere et al., 2007) were used. These cells
retained many characteristics of the intact BBB such as the expres-
sion of continuous adherens and tight junctions (see Suppl. Fig. S2),
low permeability to macromolecules (0.113  0.016  103 cm/min
for 4 kDa FITC-dextran, n¼ 11), and high transendothelial electrical
resistance (TEER ¼ 345  30 U cm2). To exclude preparations with
compromised junctional integrity, only BMVEC monolayers with
TEERs plateauing at least at 200 U cm2 were used in this study. The
blood concentrations of METH in drug abusers are in the low
micromolar range,with amediumconcentration of 1.25mM(Melega
et al., 2007). Macromolecular ﬂux of ﬂuorescent dextrans across
primary BMVEC monolayers was measured in the absence or pres-
ence of 1 mMMETH. Treatment with METH resulted in a 2.07 0.31
fold increase of 4 kDa FITC-dextran ﬂux (Fig. 1A). Signiﬁcantly, this
increase remained unchanged even when the ﬂux of considerableFig. 1. METH-induced barrier breakdown in primary BMVECs. (AeC) Macromolecular ﬂux ac
or 250 kDa FITC dextran (C). Flux was determined before and after the addition of METH (1 mM
TEER of conﬂuent BMVECs monolayers, grown on gold electrodes, was measured by imped
lysophosphatidic acid (LPA). All results shown are means  SEM of at least three independen
NT); #P < 0.05, ##P < 0.01 (Bonferroni’s post test vs METH).larger tracers was assessed (Fig. 1B and C). The effect of METH on
endothelial electrical barrier properties was also measured by
impedance spectroscopy. Impedance (and consequently the TEER)
of primary rat BMVEC monolayers was not altered by the exposure
to 1 mM METH (Fig. 1D), whereas lysophosphatidic acid produced
a strong and transient opening of the ionic barrier (Fig. 1D). Taken
together, this strongly indicated that junctional transport, which is
size-selective and also involves concomitant changes in TEER (Steed
et al., 2010), was not affected by exposure to METH.
3.2. Endothelial junction organisation in response to METH
treatment
We examined the effect of METH on the organisation of the
major junction proteins in BMVEC by immunocytochemistry fol-
lowed by confocal microscopy. In unstimulated cells, staining of VE-
cadherin (VEC), occludin and zonula occludens-1 (ZO-1) was
restricted to areas of cellecell interaction and surrounded the
entirety of each cell in uninterrupted fashion (Suppl. Fig. S2 A).
Claudin-5 immunostaining was very similar but could also be
detected on apical membranes and internal vesicles. High magni-
ﬁcation confocal microscopy showed that treatment with 1 mM
METH for 2 or 6 h did not disrupt the junctional continuity of VEC,
occludin, claudin-5 or ZO-1 staining (Fig. 2A). Furthermore, ultra-
structural analysis of inter-endothelial junction areas of BMVEC by
transmission electron microscopy (EM) revealed no discernible
changes following treatment with METH (Fig. 2B). Clearly, METH
did not affect the continuity of adherens or tight junctions.
However, in some cells it induced additional staining for VEC and
occludin in parajunctional areas (Suppl. Fig. S2 A and B). At least in
the case of VEC, diffuse parajunctional staining is thought to
represent junctional ﬂow (Kametani and Takeichi, 2007), suggest-
ing that METH did not induce global changes to inter-endothelialross primary BMVEC was assessed using 4 kDa FITC dextran (A), 70 kDa RITC dextran (B)
). Where indicated the cells were pre-treated with L-NAME (1 mM, 1 h) (grey bars). (D)
ance spectroscopy before and after the addition (arrowhead) of 1 mM METH or 10 mM
t experiments. Note that only positive SEM are shown. **P < 0.01 (Dunnett’s post test vs
Fig. 2. Effect of METH on the organisation of the interendothelial junctions. (A) ECs were either left untreated (NT) or treated with METH (1 mM) for 2 or 6 h. Subsequently, cells
were ﬁxed and stained for VEC, claudin-5, occludin and ZO-1, and then analysed by confocal microscopy. Representative projections of overlapping 0.35 mm sections spanning the
entire cell thickness showed that METH exposure did not disrupt the continuity of any junction staining. Scale bar ¼ 5 mm. (B) ECs were either left untreated (NT) or treated with
METH (1 mM) for 1 h and then analysed by transmission EM. Shown are representative images of endothelial contact areas, which appeared unchanged following METH treatment.
Space bars ¼ 100 nm.
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proteins. Importantly, METH-induced paracellular VEC and occlu-
din staining occurred evenwhen the junctional strands were intact
(Suppl. Fig. S2 C).
3.3. METH promotes endocytosis in BMVECs
Since METH-induced permeability in ECs was not paracellular,
we investigated whether the increased macromolecular ﬂux was
due to transcytosis. To test this, unidirectional, non-junctional HRP
ﬂux was measured. For this, BMVEC were allowed to take up
apically presented HRP for 1 h in the absence or presence of METH.
Then all extracellular HRP was washed off before comparing basal
HRP efﬂux rates. As shown in Fig. 3A, HRP efﬂux was increased
1.77  0.11-fold in BMVEC treated with 1 mM METH, which was
a similar increase as seen for METH-induced continuous apical-to-
basal dextran ﬂux. HRP-treated cells were further analysed by EM.DAB staining revealed the presence of HRP-containing vesicular
structures in all cells (Fig. 3B). HRP was detected in large structures
with a diameter of at least 150 nm (morphologically resembling
lysosomes), and much smaller vesicles. METH treatment did not
affect HRP uptake into the large vesicular structures (data not
shown) but signiﬁcantly increased HRP in small vesicles
[Fig. 3B(b)]. In fact, the area of such DAB staining increased nearly
1.5-fold (Fig. 3C). This was at least in part due to a signiﬁcantly
higher number of DAB-positive vesicles (Fig. 3D). Collectively, these
data demonstrated that METH induced permeability in BMVECs
was mediated by ﬂuid-phase transcytosis.
Further analysis of HRP transport indicated that METH
enhanced luminal uptake into BMVEC (Suppl. Fig. S3 and Fig. 4).
HRP uptake steadily increased withMETH treatment time, reaching
a peak at around 55 min of METH (Fig. 4A). Under these conditions,
enhanced uptake was almost exclusively restricted to METH stim-
ulation at concentrations of 1 mM, with neither lower nor higher
Fig. 3. METH enhances transcytosis in BMVECs. (A) Primary rat BMVECs were either left untreated (NT) or treated with METH (1 mM) for 1 h in the presence of horseradish
peroxidase (HRP) on the apical side of cells. HRP was then removed and the rate of its transport to the basal side determined and compared. (BeD) Uptake of HRP by primary
BMVECs visualised using transmission EM. Cells were either left untreated [B(a)] or treated with METH (1 mM) [B(b and c)] and incubated with HRP in the apical media for 1 h before
ﬁxing and processing for HRP visualisation (using DAB) and transmission EM. Shown are representative images in which electron dense DAB reaction products revealed the
presence of HRP-containing compartments. [B(c)] Additional pre-treatment with L-NAME (1 mM, 1 h) prevented METH-induced accumulation of HRP-containing structures. Scale
bar ¼ 250 nm. Densitometric quantiﬁcation of the area (C) of DAB staining or (D) number of DAB-positive vesicles per 1000 mm2 of cytoplasm, showing a signiﬁcant increase with
METH treatment. The results are expressed as mean  SEM of at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test), signiﬁcant when
compared to NT.
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the dose used throughout this study produced maximal effects.3.4. Enhanced lymphocyte transendothelial migration (TEM)
following METH treatment
The BBB not only forms a formidable regulated barrier to blood
borne molecules but also to immune and cancer cells (Greenwood
et al., 2011; Weil et al., 2005). We analysed the effect of METH on
lymphocyte TEM across primary BMVEC monolayers. Pre-
treatment with 1 mM METH for 30 min or 2 h resulted in a signiﬁ-
cant increase in the migration rate of T-cells across primary ECs
(Fig. 5A). Similarly, exposure of immortalised GPNT ECs to 1 mM
METH also enhanced TEM of T-cells (Fig. 5B). This suggested that
METH induced dysfunction of the endothelial barrier against cells
and molecules alike.3.5. eNOS mediates METH-induced effects in BMVECs
Transcytosis in ECs occurs mainly via caveolae (Predescu et al.,
2007). Since eNOS activation is functionally linked to caveolae
(Maniatis et al., 2006), endothelial permeability (Fukumura et al.,
2001; Schubert et al., 2002) and lymphocyte TEM (Martinelli
et al., 2009), we investigated whether it was involved in the
BMVEC response to METH. Activation of eNOS was determined by
measuring phosphorylation on S1177. Exposure of primary BMVECs
to 1 mM METH induced eNOS S1177 phosphorylation (Fig. 6A).
Levels of eNOS phosphorylation increased signiﬁcantly within
30 min of METH exposure, plateaued after 1 h, and persisted for at
least 2 h. We observed a similar response to METH in the GPNT
BMVEC cell line, indicating that the biochemical response to METH
was preserved even after EC immortalisation (Fig. 6B). We next
investigated whether eNOS inhibition attenuated any of the
barrier-disrupting effects of METH. Pre-treatment of primary
Fig. 4. METH enhances HRP uptake in time- and concentration-responsive manner. (A)
Primary BMVECs were treated with METH (1 mM) for the indicated times followed by
HRP (1 mg/ml) addition. After 5 min, extracellular HRP was washed off, before cell lysis
and HRP quantiﬁcation. Shown are mean levels of intracellular HRP  SEM (n ¼ 3).
*P < 0.05 (Student’s t-test), signiﬁcant when compared to time 0. (B) Primary BMVECs
were treated with METH at the indicated concentrations for 55 min. Subsequently, HRP
(1 mg/ml) was added for 5 min. Cells were extensively washed and intracellular HRP
was determined in cell lysates. Shown are mean levels of intracellular HRP  SEM
(n ¼ 10). *P < 0.05 (Student’s t-test), signiﬁcant when compared to no METH
treatment.
Fig. 5. METH enhances transendothelial lymphocyte migration. (A) Primary BMVECs
were either left untreated (NT) or treated with METH (1 mM) for the indicated times.
Cells were then washed before MBP-speciﬁc rat lymphocytes were added and allowed
to adhere and migrate for 4 h (A). Shown are adhesion (white bars) and migration rates
(black bars) as % of control cells (NT) (mean  SEM of six replicates from at least three
independent experiments) (**P < 0.01, Dunnett’s post test). Pre-incubation with L-
NAME (1 mM, 1 h) prevented the increase in migration induced by 30-min METH
(###P < 0.001, Bonferroni’s post test vs METH 30 min). (B) As in A, except that
lymphocytes were allowed to adhere and migrate across GPNT ECs for 1 h (**P < 0.01,
Student’s t-test).
Fig. 6. METH activates eNOS in BMVECs. (A) Primary BMVECs were either left
untreated (NT) or treated with METH (1 mM) for the indicated times. Total protein
extracts (ca. 50 mg) were analysed by immunoblotting with anti-phospho-S1177 eNOS
antibodies. The blot was subsequently stripped and probed for total eNOS. (B) As in A,
except that GPNT BMVECs were used. Densitometric quantiﬁcation (normalised
means  SEM) of three independent experiments is shown on the bottom of each
panel. *P < 0.05, **P < 0.01 (Dunnett’s post test vs NT).
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of macromolecular ﬂux (Fig. 1A and B, grey columns). Moreover, L-
NAME also prevented the accumulation of HRP-positive vesicles in
response to METH [Fig. 3B(c)]. Finally, pre-treatment of primary
BMVEC with L-NAME also prevented enhanced lymphocyte TEM in
response to METH (Fig. 5A). Taken together, these data indicated
that eNOS activation and NO production was central to METH-
induced barrier impairment.
3.6. Absence of effects following exposure to higher METH
concentrations
Since HRP uptake studies indicated that METH was only effec-
tive at doses around 1 mM (Fig. 4), we tested whether higher METH
concentrations affected any of the other parameters reported in
this study. Importantly, the treatment withMETH at concentrations
T. Martins et al. / Neuropharmacology 65 (2013) 74e8280of up to 100 mM for up to 24 h did not affect EC viability (Suppl.
Fig. S4). GPNT ECs were exposed to METH at concentrations
varying between 1 and 100 mM, and 1 h later, eNOS activation was
measured. In agreement with our HRP uptake studies, only expo-
sure to METH at 1 mM led to signiﬁcant eNOS activation (Fig. 7A).
Furthermore, when permeability changes across primary BMVECs
were assessed in response to 50 mM METH, we found no effect on
macromolecular ﬂux (Fig. 7B and C) or TEER (Fig. 7D). Lastly,
a higher concentration of METH (50 mM) did not affect lymphocytes
TEM either (Fig. 7E). Collectively, these data suggested that, in our
BBB in vitro models, METH led to maximal barrier disruption at
concentrations of 1 mM as judged by effects on eNOS activity, EC
permeability, vesicular uptake and lymphocyte TEM.Fig. 7. Effect of higher METH concentrations in BMVECs. (A) GPNT ECs were either left untr
eNOS phosphorylation was quantiﬁed by immunoblotting as described in Fig. 5. (**P < 0.01
dextran (C) across primary BMVECs in response to 50 mM METH was measured as describ
response to 50 mM METH as described in Fig. 1. (E) GPNT ECs were either left untreated or t
(black) was determined as described in Fig. 5.4. Discussion
METH directly damages dopaminergic and serotonergic nerve
terminals but also induces BBB dysfunction, which is thought to
contribute to its neurotoxicity (Silva et al., 2010). It is conceivable
that BBB dysfunction is an indirect result of pathophysiological
changes following METH administration, such as hyperthermia
(Kiyatkin et al., 2007). In the present study and in agreement with
published work (Ramirez et al., 2009), we demonstrate that METH
acts directly on cultured primary BMVEC to compromise their
barrier properties. In addition, we provide mechanistic evidence
that barrier breakdown was due to eNOS activation and enhanced
transcytosis.eated (NT) or treated with METH during 1 h with the indicated METH concentrations.
, Dunnett’s post test). (B, C) Changes in ﬂux of 4 kDa FITC-dextran (B) or 70 kDa RITC-
ed in Fig. 1. (D) TEER changes were measured in monolayers of primary BMVECs in
reated with METH (50 mM, 30 min) before lymphocyte adhesion (white) and migration
T. Martins et al. / Neuropharmacology 65 (2013) 74e82 81For our study, we have used primary rat BMVEC as a system of
high reproducibility and statistical robustness. We introduced
modiﬁcations to standard isolation procedures, namely selection
with puromycin (Perriere et al., 2007) and direct seeding at high
density (extensive growth periods of BMVEC lead to loss of TJ
proteins), to generate monocultures of high purity and unmatched
barrier properties as assessed by TJ protein expression and TEER.
Exposure of these cells to METH did not affect interendothelial
junction integrity. Despite mild changes to the staining pattern of
VEC and occludin, which suggested altered protein turnover, the
lateral continuity of all assessed junction proteins remained
unchanged following METH exposure. In agreement, changes in
TEER, considered a robust readout for junction opening (Steed et al.,
2010), were not observed in response to METH. Small changes in
the level of TJ proteins are seen in the METH-treated mouse brain
(Martins et al., 2011). However, it is unclear whether these changes
occur in BBB ECs and whether they result in reduced junction
integrity. Rather than enhanced paracellular permeability, we
found clear evidence for enhanced transcytosis in response to
METH. Dextrans of varying size and HRP were transported at
equally enhanced rate, suggesting that ﬂuid-phase transcytosis was
operational (Hawkins and Egleton, 2008). Furthermore, METH
induced time and concentration-dependent vesicular uptake of
HRP. In agreement with a transcellular transport pathway, EM
revealed numerous plasma membrane invaginations reminiscent
of caveolae but not HRP-positive clathrin-coated vesicles (Suppl.
Fig. S5). This is in line with the notion that caveolae are the prin-
cipal vesicular structure for transcytosis in ECs (Predescu et al.,
2007; Simionescu et al., 2009). Signiﬁcantly, METH also induces
ﬂuid-phase endocytosis in cultured neurons (Nara et al., 2010),
suggesting that this response may not be restricted to ECs. Non-
speciﬁc ﬂuid-phase transcytosis is rarely observed in the healthy
BBB endothelium (Abbott et al., 2010) but has been associated with
hypertension, hypoxia and ischemia although effector mechanisms
are unknown (Cipolla et al., 2004; Kaur and Ling, 2008). Here we
provide ﬁrst evidence that ﬂuid-phase transcytosis across BMVEC
can be directly enhanced by a small molecule, namely METH.
BBB dysfunction often results in increased leukocyte TEM.
Exposure to METH enhanced lymphocyte TEM, in agreement with
reports using a low barrier BMVEC line and monocytes (Park et al.,
2012; Ramirez et al., 2009). Leukocyte TEM utilises both para-
cellular and transcellular pathways (Muller, 2011). Since the effec-
tive dose of METH left endothelial junctions intact and increased
vesicular transport in primary BMVECs, it appears likely that
transcellular TEM was enhanced. Vesiculo-vacuolar organelles
(VVOs), which form channels for the passage of macromolecules
and are responsible for enhanced permeability in the tumour
vasculature, were initially suggested as possible endothelial struc-
tures that could mediate transcellular migration (Hordijk, 2006).
Subsequently, Muller and co-workers showed that the lateral
border recycling compartment (LBRC), a membrane reticulum
involved in membrane and junction protein trafﬁcking in cell
border areas of ECs, is implicated in regulating both transcellular
and paracellular TEM (Muller, 2011). As judged by transmission EM,
METH typically induced HRP uptake into large groups of juxtapo-
sitional vesicular structures, which were restricted to a single area
of the cell (as illustrated in Fig. 3). Since images were derived from
70 nm thick sections it was impossible to determine whether HRP
was taken up into isolated vesicles or a reticulum similar or iden-
tical to the LBRC. Thus, METH may inﬂuence membrane availability
and/or dynamics of the LBRC or the VVOs and thus diminish barrier
properties to molecules and cells in BMVECs.
Both METH-enhanced transcytosis and TEM were sensitive to
pre-treatment with the NOS inhibitor L-NAME. Since effective doses
of METH also led to robust eNOS activation and iNOS could not bedetected at any time during our experiments (data not shown), we
conclude that eNOS activation and consequent NO production are
key factors of METH-induced BBB breakdown. Activation of
neuronal NOS and the production of NO and derivatives also occur
in METH-stimulated neurons and have been implicated in associ-
ated dopaminergic neurotoxicity (Imam et al., 2000), suggesting
again that cellular METH targets may be similar in neurons and ECs.
In the endothelium, eNOS is instrumental in regulating vascular
permeability (Fukumura et al., 2001; Schubert et al., 2002). Acti-
vation of eNOS and NO production are also limiting factors of
lymphocyte TEM across BMVEC (Martinelli et al., 2009). Thus, by
activating eNOS, METH clearly modulated a central regulator of
BMVEC barrier function. Most cytotoxicity associated with NO is
due to peroxynitrite, the reaction product between NO and the
superoxide anion (Pacher et al., 2007). Our study did not address
whether barrier breakdown was merely due to NO or rather per-
oxynitrite. However, acute microvascular permeability and
lymphocyte TEM are mainly dependent on NO but not superoxide
production (Duran et al., 2010; Martinelli et al., 2009). Furthermore,
we were unable to detect any cytotoxicity in BMVEC in response to
METH, suggesting that oxidative stress and peroxynitrite produc-
tion was not induced.
Typical METH abuse leads to accumulation of the drug in blood
plasma at sub or low micromolar concentrations (Cook et al., 1992;
Harris et al., 2003; Melega et al., 2007). In primary rat BMVEC, HRP
uptake and eNOS activation were only observed in response to
METH at ca. 1 mM. In agreement, endothelial barrier dysfunction
was observed at low but not high micromolar concentrations of
METH, suggesting that the BBB is compromised under typical abuse
conditions. This raises the possibility that several targets with
different afﬁnities for METH exist in ECs. Alternatively, higher
concentrations of METH may induce rapid down-regulation of the
EC response and render it undetectable. Finally, higher METH
concentration may also lead to the activation of another signalling
pathway counteracting the primary response described in this
report. Indeed, higher concentrations of METH lead to the genera-
tion of ROS (Fleckenstein et al., 2007; Park et al., 2012; Ramirez
et al., 2009), which may subsequently neutralise the bioavailable
NO. Nevertheless, it is unclear whether research into the BMVEC
response to higher METH concentration is justiﬁed since concen-
trations of METH higher than 30 mM are associated with lethality in
humans (Takayasu et al., 1995).
In summary, our results suggest that METH-induced opening of
the BBB involves eNOS/NO-mediated transcytosis. Apart from
providing important mechanistic insight into METH-induced
neurotoxicity, our work also identiﬁes a potentially novel strategy
for drug delivery into the brain. METH has been suggested for such
use before (Kast, 2009), but our ﬁnding of a link to non-speciﬁc
ﬂuid-phase transcytosis, which is usually absent at the BBB,
increases the signiﬁcance of potential use for this purpose. To fully
assess the possibility of agonist-induced opening of the BBB, future
work should focus on identifying the endothelial targets of METH
and the structural determinants of METH that are important for
BMVEC deregulation. Potentially, this could lead to the design of
non-psychostimulatory METH derivatives that maintain the
capacity to transiently open the BBB without associated toxicity to
monoaminergic nerve terminals.
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